USA - NASDAQ:BEAT - US42238H1086 - Common Stock
The current stock price of BEAT is 1.59 USD. In the past month the price decreased by -3.03%. In the past year, price decreased by -35.74%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.04 | 217.45B | ||
| ISRG | INTUITIVE SURGICAL INC | 61.83 | 190.85B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.35 | 150.15B | ||
| SYK | STRYKER CORP | 28.84 | 141.68B | ||
| MDT | MEDTRONIC PLC | 16.52 | 117.17B | ||
| BDX | BECTON DICKINSON AND CO | 12.64 | 51.69B | ||
| IDXX | IDEXX LABORATORIES INC | 52.42 | 50.36B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.42 | 48.91B | ||
| RMD | RESMED INC | 26.44 | 36.85B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.54 | 34.66B | ||
| DXCM | DEXCOM INC | 40.35 | 26.90B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.29 | 26.36B |
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. The company is headquartered in Santa Clara, California and currently employs 19 full-time employees. The company went IPO on 2021-10-14. The firm focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. The company is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. The company is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. The company is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.
HEARTBEAM INC
2118 Walsh Ave., Suite 210
Santa Clara CALIFORNIA 19355 US
CEO: Joseph H. Capper
Employees: 19
Phone: 14088994443
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. The company is headquartered in Santa Clara, California and currently employs 19 full-time employees. The company went IPO on 2021-10-14. The firm focuses on developing and commercializing higher resolution ambulatory Electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease both inside and outside a healthcare facility setting. The company is engaged in the development of higher resolution ECG solutions is achieved through the development of the Company’s proprietary and patented electrocardiography technology platform. The company is developing three-dimensional (3D) representations of cardiac electrical activity by displaying the spatial locations of ECG waveforms. The company is developing its own product, the HeartBeam System. The HeartBeam System comprises a credit card sized 12-lead output electrocardiogram device, a patient application, a physician portal, and powerful cloud-based algorithms. The core technology consists of a series of patented inventions that allow it to capture the heart’s electrical activity from three distinct directions.
The current stock price of BEAT is 1.59 USD. The price decreased by -0.63% in the last trading session.
BEAT does not pay a dividend.
BEAT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
BEAT stock is listed on the Nasdaq exchange.
8 analysts have analysed BEAT and the average price target is 4.59 USD. This implies a price increase of 188.68% is expected in the next year compared to the current price of 1.59.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BEAT.
ChartMill assigns a technical rating of 4 / 10 to BEAT. When comparing the yearly performance of all stocks, BEAT turns out to be only a medium performer in the overall market: it outperformed 64.81% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to BEAT. While BEAT seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months BEAT reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -9.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -340.14% | ||
| ROE | -486.47% | ||
| Debt/Equity | 0 |
8 analysts have analysed BEAT and the average price target is 4.59 USD. This implies a price increase of 188.68% is expected in the next year compared to the current price of 1.59.